目的 觀察補(bǔ)中益氣顆粒聯(lián)合曲美布汀治療脾胃虛弱證腹瀉型腸易激綜合征的臨床療效。方法 選取2015年6月-2016年5月在天津中醫(yī)藥大學(xué)第一附屬醫(yī)院脾胃科門診就診的脾胃虛弱證腹瀉型腸易激綜合征患者60例，每組各30例。對照組患者口服馬來酸曲美布汀片，0.2 g/次，3次/d。治療組在對照組的基礎(chǔ)上口服補(bǔ)中益氣顆粒，3 g/次，3次/d。兩組患者均連續(xù)治療4周。觀察兩組患者臨床療效，比較治療前后兩組癥狀積分、排便情況和焦慮抑郁癥狀評分的變化。結(jié)果 治療后，對照組和治療組的總有效率分別為83.33%和96.67%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者腹瀉、腹痛、腹脹積分均較治療前明顯下降（P<0.01）；且治療組低于對照組（P<0.01）。治療后，兩組患者日排便次數(shù)及10 d內(nèi)排便急迫天數(shù)均較治療前降低（P<0.05）；且治療后治療組優(yōu)于對照組（P<0.05）。治療后，兩組SAS評分、SDS評分均較治療前顯著降低（P<0.05）；且治療后治療組SAS和SDS評分優(yōu)于對照組（P<0.05）。結(jié)論 補(bǔ)中益氣顆粒聯(lián)合曲美布汀對脾胃虛弱證腹瀉型腸易激綜合征療效確切，具有一定的臨床推廣應(yīng)用價值。

Objective To observe the clinical efficacy of Buzhong Yiqi Granules combined with trimebutine in treatment of irritable bowel syndrome of diarrhea type with spleen and stomach deficiency. Methods Patients (60 cases) with irritable bowel syndrome of diarrhea type with spleen and stomach deficiency in First Teaching Hospital of Tianjin University of TCM from June 2015 to May 2016 were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were po administered with Trimebutine Maleate Tablets, 0.2 g/time, three times daily. Patients in the treatment group were po administered with Buzhong Yiqi Granules on the basis of the control group, 3 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and symptom scores, defecation, SAS and SDS scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.33% and 96.67% respectively, and there was difference between two groups (P<0.05). After treatment, the diarrhea, abdominal pain, abdominal distension scores in two groups were significantly decreased (P<0.01). And the symptom scores of the treatment group were significantly lower than those in the control group (P<0.01). After treatment, the daily defecation frequency and days of defecation urgency in 10 d in two groups were significantly decreased (P<0.05). And those indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the SAS and SDS scores in two groups were significantly decreased (P<0.05). The SAS and SDS scores in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Buzhong Yiqi Granules combined with trimebutine has a reliable clinical curative effect in treatment of irritable bowel syndrome of diarrhea type with spleen and stomach deficiency, which has a certain clinical application value.